Current Report Filing (8-k)
October 31 2018 - 9:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 31, 2018
STRONGBRIDGE BIOPHARMA plc
(Exact name of registrant as specified in its charter)
Ireland
(State or other
jurisdiction of incorporation)
|
|
001-37569
(Commission
File Number)
|
|
98-1275166
(I.R.S. Employer
Identification No.)
|
900 Northbrook Drive
Suite 200
Trevose, PA
(Address of principal executive offices)
|
|
19053
(Zip Code)
|
Registrants telephone number, including area code:
(610) 254-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 2.02
Results of Operations and Financial Condition.
On October 31, 2018, Strongbridge Biopharma plc (the Company) issued a press release reporting third quarter financial results and providing a corporate update. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished to the Commission and shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. The information in Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the Securities Act), except as expressly set forth by specific reference in such filing. The information set forth herein will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 7.01
Regulation FD.
The response to Item 2.02 is incorporated herein by reference to this Item 7.01.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
STRONGBRIDGE BIOPHARMA PLC
|
|
|
|
|
By:
|
/s/ A. Brian Davis
|
|
Name:
|
A. Brian Davis
|
|
Title:
|
Chief Financial Officer
|
|
|
|
Date: October 31, 2018
|
|
|
3
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2024 to May 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From May 2023 to May 2024